Vortioxetine

Generic Name: Vortioxetine

Brand Names: Brintellix, Trintellix

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₂N_₂S

CAS Number: 508233-74-7

Unique Ingredient Identifier: 3O2K1S3WQV

Background: Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of se...

Indication: 用于治疗重度抑郁症成人患者。

Associated Conditions: Major Depressive Disorder (MDD)

Associated Therapies: -

Clinical Trials

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine

First Posted Date: 2016-11-23

Last Posted Date: 2019-07-11

Lead Sponsor: Takeda

Target Recruit Count: 123

Registration Number: NCT02972632

Locations: 🇺🇸
University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States
🇺🇸
Novex Clinical Research, LLC, New Bedford, Massachusetts, United States
🇺🇸
University of South Florida, Tampa, Florida, United States

and more 22 locations

Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine

Phase 4

Terminated

Conditions: Depressive Disorder
Major Depression
Depression
Depression, Unipolar

Interventions: Drug: Vortioxetine

First Posted Date: 2016-11-21

Last Posted Date: 2019-10-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 2

Registration Number: NCT02969876

Locations: 🇺🇸
the Massachusetts General Hospital, Boston, Massachusetts, United States

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Phase 4

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vortioxetine
Drug: Paroxetine
Drug: Placebo

First Posted Date: 2016-10-13

Last Posted Date: 2018-09-14

Lead Sponsor: Takeda

Target Recruit Count: 361

Registration Number: NCT02932904

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Phase 3

Terminated

Conditions: Depressive Disorder, Major

Interventions: Drug: Vortioxetine

First Posted Date: 2016-08-18

Last Posted Date: 2022-12-28

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 662

Registration Number: NCT02871297

Locations: 🇿🇦
Cape Trial Centre, Bellville, Cape Town, South Africa
🇬🇧
NHS Greater Glasgow and Clyde Glasgow Clinical Research Facility-Queen Elizabeth University Hospi..., Glasgow, United Kingdom
🇪🇸
Hospital General Universitario Gregorio Maranon, Madrid, Spain

and more 75 locations

Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)

Phase 3

Withdrawn

Conditions: Major Depression
TBI

Interventions: Drug: Placebo
Drug: Vortioxetine

First Posted Date: 2016-07-27

Last Posted Date: 2016-09-02

Lead Sponsor: Johns Hopkins University

Registration Number: NCT02845349

The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: vortioxetine

First Posted Date: 2016-04-25

Last Posted Date: 2021-10-04

Lead Sponsor: Rush University Medical Center

Target Recruit Count: 31

Registration Number: NCT02749721

Locations: 🇺🇸
Rush University Medical Center, Skokie, Illinois, United States

Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers

Phase 4

Withdrawn

Conditions: Unipolar Major Depression
Stage I, II or III Breast Cancer

Interventions: Drug: Vortioxetine

First Posted Date: 2015-12-22

Last Posted Date: 2016-09-30

Lead Sponsor: University of Miami

Registration Number: NCT02637466

Vortioxetine for Posttraumatic Stress Disorder

Phase 4

Completed

Conditions: Post-Traumatic Stress Disorder

Interventions: Drug: Placebo
Drug: Vortioxetine

First Posted Date: 2015-12-22

Last Posted Date: 2021-02-08

Lead Sponsor: University of Miami

Target Recruit Count: 41

Registration Number: NCT02637895

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

Vortioxetine for Binge Eating Disorder

Phase 2

Completed

Conditions: Binge Eating Disorder

Interventions: Drug: Placebo
Drug: Vortioxetine

First Posted Date: 2015-08-19

Last Posted Date: 2020-11-23

Lead Sponsor: University of Chicago

Target Recruit Count: 80

Registration Number: NCT02528409

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

Early Phase 1

Withdrawn

Conditions: Coronary Artery Disease
Major Depressive Disorder

Interventions: Drug: Vortioxetine

First Posted Date: 2015-05-27

Last Posted Date: 2016-08-25

Lead Sponsor: Thomas Jefferson University

Registration Number: NCT02454426

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy